Atossa Therapeutics, Inc. (ATOS): Total Liabilities
$8.26M
As of 2025-12-31
$5.45M
As of 2026-06-30
+14.0%
3-year compound annual growth
-12.0%
5-year compound annual growth
+12.7%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.26M | +66.2% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $4.97M | -5.1% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $5.24M | -6.0% | 2025-03-25, Balance as of period end |
| 2022-12-31 | $5.57M | +78.1% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $3.13M | -80.1% | 2023-03-22, Balance as of period end |
| 2020-12-31 | $15.67M | n/m | 2022-02-28, Balance as of period end |
| 2019-12-31 | $1.33M | -54.2% | 2021-03-31, Balance as of period end |
| 2018-12-31 | $2.92M | n/a | 2020-03-26, Balance as of period end |
| No annual figure between 2016-12-31 and 2018-12-31. | |||
| 2016-12-31 | $1.05M | -58.1% | 2017-03-21, Balance as of period end |
| 2015-12-31 | $2.50M | +10.4% | 2017-03-21, Balance as of period end |
| 2014-12-31 | $2.27M | +61.0% | 2016-03-30, Balance as of period end |
| 2013-12-31 | $1.41M | n/a | 2015-03-30, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Atossa Therapeutics, Inc. (ATOS) | 2025-12-31 | $8.26M | +66.2% |
| Akari Therapeutics Plc (AKTX) | 2025-12-31 | $19.56M | -30.9% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $22.39M | -65.0% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $13.04M | -6.5% |
| Unicycive Therapeutics, Inc. (UNCY) | 2025-12-31 | $18.94M | -21.9% |
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | $5.00M | -67.6% |
| Medicinova Inc (MNOV) | 2025-12-31 | $4.02M | +19.1% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $6.92M | +45.1% |
| NextCure, Inc. (NXTC) | 2025-12-31 | $15.24M | -1.0% |
Compare ATOS, AKTX, VRCA, VTGN side by side · Screen every company in Pharmaceutical Preparations ↗